The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
TCL
Vol.
40
No.
14
April 04, 2014
- Group Chairs: Research In “Crisis” ASCO Says NCTN Budgets Cut By 40 Percent, Warns of “Dangerous Disruption of Cancer Care”
- AACR, ASCO Publish Reports Examining U.S. Cancer Care
- Oncologists Tell Congress Community Cancer Practices Are Not Adequately Reimbursed
- AACR Academy Names 2014 Class of Fellows
- In Brief: PCORI Forms Clinical Trials Advisory Board
TCL
Vol.
40
No.
15
April 11, 2014
- Varmus Pledges No Funding Gap for NCORP, Blames Snafu On “Unclear Communication”
- What the Physician Pay Report Won’t Tell You
- Obama Signs Law Authorizing $126 Million Over 10 Years for Pediatric Research
- AACR Presents 2014 Awards, Arteaga Becomes President at Annual Meeting
- In Brief: Goldsmith Named CEO of CancerCare
TCL
Vol.
40
No.
16
April 18, 2014
TCL
Vol.
40
No.
17
April 25, 2014
- No Justification Provided: DePinho’s Nixing of Tenure Renewals May Bring Censure to MD Anderson
- Itri Pays Fine, Agrees Not to Serve As Company Officer for Five Years
- ASCO Releases Three Guidelines For Cancer Survivorship Care
- In Brief: Morgan Named Director Of UAMS Myeloma Institute
- FDA Approvals: Cobas HPV Test Approved For Primary Cervical Screening
CCL
Vol.
37
No.
4
April 25, 2014
- FDA Approves Cyramza for Stomach Cancer; Zykadia in NSCLC; Lipiodol for HCC Imaging; And Cobas HPV Test for Primary Screening
- Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival
- Oral Sorafenib Trial Published in The Lancet; Tablets Extend PFS in Metastatic Disease
- Phase III Trial Fails to Extend OS After Meeting Primary Endpoint Of Durable Response Rate
- Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen
- Palbocicilib Doubles PFS In Phase II Trial to 20.2 Months
- LDK378 Demonstrates 58 Percent Overall Response Rate in Phase I
- ASCO Releases Three Guidelines For Cancer Survivorship Care
- NCI CTEP Approved Trials For the Month of April
TCL
Vol.
40
No.
19
May 09, 2014
- Oregon Center Launching $1 Billion Program To Identify Lethal Cancers Before They Kill
- CMS Advisors Express Low Confidence In Low-Dose CT Screening for Lung Cancer
- Bach: LCA Center Certification Untrustworthy; CISNET Models Don’t Match
- Steven Woolf: Why CMS Should Not Cover LDCT
- Growth Of The Cost of Drugs Slows to 5.4 Percent per Year; 21 Therapies Launched in 2 Years
- Women’s Health Initiative Trial Produced $37.1 Billion in Returns
- FDA Oncology Unit Fastest in Approvals Despite Having Highest Workload
- In Brief: David Cole Named President of The Medical University of South Carolina
- Drug Approvals; Zykadia Granted Accelerated Approval For ALK+ NSCLC; ADXS-HPV Grated Orphan Drug Designation
TCL
Vol.
40
No.
20
May 16, 2014
- Over $20 Million Carved Out From Statistical, Operations Centers
- No Justification Provided: AAUP Demands Reinstatement of Faculty Denied Tenure Renewal at MD Anderson
- Report: Rising Treatment Costs Due to 340B Discounts
- TGen and George Mason Form Precision Medicine Alliance
- In Brief: Oncology Nursing Society Names Board Of Directors